JPWO2021097157A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021097157A5 JPWO2021097157A5 JP2022527987A JP2022527987A JPWO2021097157A5 JP WO2021097157 A5 JPWO2021097157 A5 JP WO2021097157A5 JP 2022527987 A JP2022527987 A JP 2022527987A JP 2022527987 A JP2022527987 A JP 2022527987A JP WO2021097157 A5 JPWO2021097157 A5 JP WO2021097157A5
- Authority
- JP
- Japan
- Prior art keywords
- vector construct
- c1ei
- composition
- functional
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013598 vector Substances 0.000 claims description 57
- 239000002245 particle Substances 0.000 claims description 46
- 229940009550 c1 esterase inhibitor Drugs 0.000 claims description 40
- 102000055157 Complement C1 Inhibitor Human genes 0.000 claims description 36
- 108050007539 Plasma protease C1 inhibitor Proteins 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 30
- 241000124008 Mammalia Species 0.000 claims description 26
- 241000702421 Dependoparvovirus Species 0.000 claims description 25
- 210000004185 liver Anatomy 0.000 claims description 18
- 210000004027 cell Anatomy 0.000 claims description 16
- 210000000234 capsid Anatomy 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 230000001105 regulatory effect Effects 0.000 claims description 12
- 230000002103 transcriptional effect Effects 0.000 claims description 12
- 150000007523 nucleic acids Chemical group 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 239000003623 enhancer Substances 0.000 claims description 8
- 102000013918 Apolipoproteins E Human genes 0.000 claims description 6
- 108010025628 Apolipoproteins E Proteins 0.000 claims description 6
- 108090000565 Capsid Proteins Proteins 0.000 claims description 6
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 6
- 206010019860 Hereditary angioedema Diseases 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 230000008488 polyadenylation Effects 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 239000002753 trypsin inhibitor Substances 0.000 claims description 6
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 230000007812 deficiency Effects 0.000 claims description 4
- 206010030113 Oedema Diseases 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 2
- 241000282693 Cercopithecidae Species 0.000 claims description 2
- 102000001554 Hemoglobins Human genes 0.000 claims description 2
- 108010054147 Hemoglobins Proteins 0.000 claims description 2
- 241000238631 Hexapoda Species 0.000 claims description 2
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 2
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 2
- 239000000854 Human Growth Hormone Substances 0.000 claims description 2
- 241001504519 Papio ursinus Species 0.000 claims description 2
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 claims description 2
- 239000007900 aqueous suspension Substances 0.000 claims description 2
- 230000036765 blood level Effects 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000013608 rAAV vector Substances 0.000 claims description 2
- 230000010076 replication Effects 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 230000010415 tropism Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 20
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962935359P | 2019-11-14 | 2019-11-14 | |
| US62/935,359 | 2019-11-14 | ||
| US202063016365P | 2020-04-28 | 2020-04-28 | |
| US63/016,365 | 2020-04-28 | ||
| PCT/US2020/060337 WO2021097157A1 (en) | 2019-11-14 | 2020-11-13 | Treatment of hereditary angioedema with liver-specific gene therapy vectors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023503850A JP2023503850A (ja) | 2023-02-01 |
| JPWO2021097157A5 true JPWO2021097157A5 (fi) | 2023-11-20 |
Family
ID=73834586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022527987A Pending JP2023503850A (ja) | 2019-11-14 | 2020-11-13 | 肝臓特異的遺伝子療法ベクターによる遺伝性血管浮腫の治療 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230340078A1 (fi) |
| EP (1) | EP4058475A1 (fi) |
| JP (1) | JP2023503850A (fi) |
| KR (1) | KR20220098210A (fi) |
| CN (1) | CN114829391A (fi) |
| AU (1) | AU2020384294A1 (fi) |
| BR (1) | BR112022009279A2 (fi) |
| CA (1) | CA3161154A1 (fi) |
| CL (1) | CL2022001260A1 (fi) |
| CO (1) | CO2022005641A2 (fi) |
| IL (1) | IL292717A (fi) |
| MX (1) | MX2022005869A (fi) |
| TW (1) | TW202128733A (fi) |
| WO (1) | WO2021097157A1 (fi) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230078805A (ko) | 2020-11-02 | 2023-06-02 | 바이오마린 파머수티컬 인크. | 아데노-연관 바이러스의 농축 공정 |
| AU2022292164A1 (en) * | 2021-06-17 | 2024-02-01 | Meiragtx Uk Ii Limited | Aav manufacturing methods |
| AR127217A1 (es) | 2021-10-01 | 2023-12-27 | Biomarin Pharm Inc | Tratamiento de angioedema hereditario con vectores de genoterapia de aav y formulaciones terapéuticas |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| EP0127839B1 (en) | 1983-05-27 | 1992-07-15 | THE TEXAS A&M UNIVERSITY SYSTEM | Method for producing a recombinant baculovirus expression vector |
| ZA848495B (en) | 1984-01-31 | 1985-09-25 | Idaho Res Found | Production of polypeptides in insect cells |
| US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
| WO2003033710A1 (fr) | 2001-10-16 | 2003-04-24 | National Institute Of Advanced Industrial Science And Technology | Nouvelle n-acetylglucosamine transferase, acide nucleique codant cette enzyme, anticorps dirige contre cette enzyme et utilisation de l'enzyme pour diagnostiquer un cancer ou une tumeur |
| US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| EP2338900B1 (en) | 2001-11-13 | 2014-01-01 | The Trustees of The University of Pennsylvania | Adeno-associated virus (AAV) Cy.5 sequences, vectors containing the same and uses thereof |
| WO2003074714A1 (en) | 2002-03-05 | 2003-09-12 | Stichting Voor De Technische Wetenschappen | Baculovirus expression system |
| US7943379B2 (en) | 2008-04-30 | 2011-05-17 | Nationwide Children's Hospital, Inc. | Production of rAAV in vero cells using particular adenovirus helpers |
| RU2653444C2 (ru) | 2012-02-17 | 2018-05-08 | Дзе Чилдрен'З Хоспитал Оф Филадельфия | Композиции вектора aav и способы переноса генов в клетки, органы и ткани |
| PE20160188A1 (es) * | 2013-07-22 | 2016-04-27 | Philadelphia Children Hospital | Variantes aav y composiciones, metodos y usos para transferencia de gen a celulas, organos y tejidos |
| AU2016267687B2 (en) * | 2015-05-28 | 2022-04-07 | Cornell University | Adeno-associated virus mediated delivery of C1EI as a therapy for angioedema |
| SG11201811603WA (en) | 2016-07-26 | 2019-02-27 | Biomarin Pharm Inc | Novel adeno-associated virus capsid proteins |
| WO2019143272A1 (en) * | 2018-01-16 | 2019-07-25 | Cls Therapeutics Limited | Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (dnase) activity |
-
2020
- 2020-11-13 KR KR1020227019436A patent/KR20220098210A/ko active Search and Examination
- 2020-11-13 CA CA3161154A patent/CA3161154A1/en active Pending
- 2020-11-13 CN CN202080087888.0A patent/CN114829391A/zh active Pending
- 2020-11-13 WO PCT/US2020/060337 patent/WO2021097157A1/en active Application Filing
- 2020-11-13 US US17/777,690 patent/US20230340078A1/en active Pending
- 2020-11-13 MX MX2022005869A patent/MX2022005869A/es unknown
- 2020-11-13 EP EP20824369.1A patent/EP4058475A1/en active Pending
- 2020-11-13 BR BR112022009279A patent/BR112022009279A2/pt unknown
- 2020-11-13 TW TW109139830A patent/TW202128733A/zh unknown
- 2020-11-13 JP JP2022527987A patent/JP2023503850A/ja active Pending
- 2020-11-13 AU AU2020384294A patent/AU2020384294A1/en active Pending
-
2022
- 2022-04-29 CO CONC2022/0005641A patent/CO2022005641A2/es unknown
- 2022-05-03 IL IL292717A patent/IL292717A/en unknown
- 2022-05-13 CL CL2022001260A patent/CL2022001260A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230374547A1 (en) | Cns gene delivery using peripheral administration of aav vectors | |
| US20240109938A1 (en) | Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof | |
| US11419920B2 (en) | Factor VIII sequences | |
| US10308957B2 (en) | rAAV vectors and methods for transduction of photoreceptors and RPE cells | |
| JP7347933B2 (ja) | 血友病ａ治療に対する遺伝子療法 | |
| JP2021514201A (ja) | ハイブリッド調節要素 | |
| US20220281923A1 (en) | Aav capsid variants for gene therapy | |
| CN113518628A (zh) | 治疗威尔逊病的基因疗法构建体 | |
| US20230175015A1 (en) | Immunosuppressive agents and viral delivery re-dosing methods for gene therapy | |
| CN111218446A (zh) | 一种肝脏特异性启动子及其应用 | |
| EP4159863A1 (en) | Codon-optimized nucleic acid encoding smn1 protein | |
| CA3207268A1 (en) | Compositions and methods for treating hereditary angioedema | |
| JPWO2021097157A5 (fi) | ||
| US20210000973A1 (en) | Recombinant adeno-associated viruses encoding serpin peptides and uses thereof | |
| US20240076691A1 (en) | Codon-optimized nucleic acid encoding the fix protein | |
| OA21369A (en) | Codon-optimized nucleic acid encoding the fix protein. |